Prostate Cancer Research

At City of Hope, prostate cancer clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. Our patients have access to a wide variety of clinical trials, including innovative chemotherapy, targeted therapies and hormone therapies with fewer side effects, as well as advanced surgical techniques, radiation approaches and prevention strategies.

What Are Your Prostate Cancer Research Projects?

  • Using focused ultrasound to heat up and destroy prostate cancer
  • Identifying and incorporating biomarkers for better detection of prostate cancer development, progression and recurrence, possibly bypassing the need for biopsies to make a diagnosis
  • Using neural stem cells to target and deliver cancer-fighting drugs to prostate cancer cells throughout the body
  • New imaging methods to detect microscopic disease outside the prostate
  • Using re-engineered immune cells to target and attack prostate cancer throughout the body
  • Examining the benefits of surgery for patients with metastatic prostate cancer
  • Use of natural therapies, such as white mushroom powder, to help prevent prostate cancer recurrence
  • Long-term follow-up with prostate cancer survivors to detect and manage long-term effects and improve their quality of life

What Are the Ongoing Clinical Trials for Prostate Cancer?

  • PSCA-targeted CAR T cell therapy for mCRPC (NCT03873805)
    • This Phase 1 trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to other places in the body (metastatic).
  • ADT + abiraterone + talazoparib in mHSPC, enriched for diverse population (NCT04734730)
    • The goal of this Phase 2 trial is to increase the efficacy of first-line therapy for men with metastatic castration-sensitive prostate cancer by adding the PARP inhibitor talazoparib to standard therapy with androgen deprivation therapy (ADT) + abiraterone acetate (abiraterone).
  • Oligometastatic prostate protocol (NCT03361735)
    • This Phase 2 trial studies radium Ra 223 dichloride, hormone therapy (using leuprolide acetate or goserelin acetate) and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
  • White button mushroom trial for BCR and active surveillance (NCT04519879)
    • This Phase 2 trial studies how well a white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with recurrent or therapy-naïve prostate cancer. A white button mushroom supplement may affect PSA levels, various parameters of the immune system and levels of hormones that may have a role in prostate cancer growth.
  • SIMCAP (Surgery in Metastatic Carcinoma of Prostate) (NCT03456843)
    • This randomized Phase 2 trial studies how well surgical removal of the prostate and antiandrogen therapy (with or without docetaxel) work in treating men with newly diagnosed metastatic prostate cancer.

Compassionate patient care means commitment to research. Not only do our clinical trials give current patients access to promising, leading-edge therapies — they also improve overall care for future patients worldwide. Look up our current studies and their eligibility criteria.